dijous, 26 de gener del 2017

Johnson & Johnson to pay $30B for Actelion

Johnson & Johnson to pay $30B for ActelionAfter weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last month.

The companies plan to spin off Actelion’s research and development pipeline into a new company, led by Actelion CEO Jean-Paul Clozel.

Get the full story at our sister site, Drug Delivery Business News.

The post Johnson & Johnson to pay $30B for Actelion appeared first on MassDevice.



from MassDevice http://ift.tt/2kwR57Y

Cap comentari:

Publica un comentari a l'entrada